FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139804581> ?p ?o ?g. }

• W2139804581 endingPage "838" @default.
• W2139804581 startingPage "830" @default.
• W2139804581 abstract "Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie, common mutations). However, a subset of patients (10%) with mutations in EGFR have tumours that harbour uncommon mutations. There is a paucity of data regarding the sensitivity of these tumours to EGFR inhibitors. Here we present data for the activity of afatinib in patients with advanced non-small-cell lung cancer that have tumours harbouring uncommon EGFR mutations.In this post-hoc analysis, we used prospectively collected data from tyrosine kinase inhibitor-naive patients with EGFR mutation-positive advanced (stage IIIb-IV) lung adenocarcinomas who were given afatinib in a single group phase 2 trial (LUX-Lung 2), and randomised phase 3 trials (LUX-Lung 3 and LUX-Lung 6). Analyses were done in the intention-to-treat population, including all randomly assigned patients with uncommon EGFR mutations. The type of EGFR mutation (exon 19 deletion [del19], Leu858Arg point mutation in exon 21, or other) and ethnic origin (LUX-Lung 3 only; Asian vs non-Asian) were pre-specified stratification factors in the randomised trials. We categorised all uncommon mutations as: point mutations or duplications in exons 18-21 (group 1); de-novo Thr790Met mutations in exon 20 alone or in combination with other mutations (group 2); or exon 20 insertions (group 3). We also assessed outcomes in patients with the most frequent uncommon mutations, Gly719Xaa, Leu861Gln, and Ser768Ile, alone or in combination with other mutations. Response was established by independent radiological review. These trials are registered with ClinicalTrials.gov, numbers NCT00525148, NCT00949650, and NCT01121393.Of 600 patients given afatinib across the three trials, 75 (12%) patients had uncommon EGFR mutations (38 in group 1, 14 in group 2, 23 in group 3). 27 (71·1%, 95% CI 54·1-84·6) patients in group 1 had objective responses, as did two (14·3%, 1·8-42·8) in group 2 and two (8·7%, 1·1-28·0) in group 3. Median progression-free survival was 10·7 months (95% CI 5·6-14·7) in group 1, 2·9 months (1·2-8·3) in group 2; and 2·7 months (1·8-4·2) in group 3. Median overall survival was 19·4 months (95% CI 16·4-26·9) in group 1, 14·9 months (8·1-24·9) in group 2, and 9·2 months (4·1-14·2) in group 3. For the most frequent uncommon mutations, 14 (77·8%, 95% CI 52·4-93·6) patients with Gly719Xaa had an objective response, as did nine (56·3%, 29·9-80·2) with Leu861Gln, and eight (100·0%, 63·1-100·0) with Ser768Ile.Afatinib was active in non-small-cell lung cancer tumours that harboured certain types of uncommon EGFR mutations, especially Gly719Xaa, Leu861Gln, and Ser768Ile, but less active in other mutations types. Clinical benefit was lower in patients with de-novo Thr790Met and exon 20 insertion mutations. These data could help inform clinical decisions for patients with non-small-cell lung cancer harbouring uncommon EGFR mutations.Boehringer Ingelheim." @default.
• W2139804581 created "2016-06-24" @default.
• W2139804581 creator A5006820907 @default.
• W2139804581 creator A5032337115 @default.
• W2139804581 creator A5036507802 @default.
• W2139804581 creator A5038306289 @default.
• W2139804581 creator A5041640815 @default.
• W2139804581 creator A5052670273 @default.
• W2139804581 creator A5052962058 @default.
• W2139804581 creator A5053546904 @default.
• W2139804581 creator A5065884417 @default.
• W2139804581 creator A5066717752 @default.
• W2139804581 creator A5072123060 @default.
• W2139804581 creator A5075333926 @default.
• W2139804581 creator A5081371583 @default.
• W2139804581 date "2015-07-01" @default.
• W2139804581 modified "2023-10-14" @default.
• W2139804581 title "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6" @default.
• W2139804581 cites W1967394241 @default.
• W2139804581 cites W1994499102 @default.
• W2139804581 cites W1999074023 @default.
• W2139804581 cites W2002937040 @default.
• W2139804581 cites W2005728761 @default.
• W2139804581 cites W2037873277 @default.
• W2139804581 cites W2043696829 @default.
• W2139804581 cites W2053603900 @default.
• W2139804581 cites W2076883919 @default.
• W2139804581 cites W2094771796 @default.
• W2139804581 cites W2096198395 @default.
• W2139804581 cites W2098395191 @default.
• W2139804581 cites W2101329867 @default.
• W2139804581 cites W2111662961 @default.
• W2139804581 cites W2113521542 @default.
• W2139804581 cites W2114642822 @default.
• W2139804581 cites W2130254323 @default.
• W2139804581 cites W2130784618 @default.
• W2139804581 cites W2132157071 @default.
• W2139804581 cites W2132870547 @default.
• W2139804581 cites W2149733252 @default.
• W2139804581 cites W2151016309 @default.
• W2139804581 cites W2154130790 @default.
• W2139804581 cites W2160336497 @default.
• W2139804581 cites W2160982674 @default.
• W2139804581 cites W2166084034 @default.
• W2139804581 cites W2167934111 @default.
• W2139804581 cites W2168554121 @default.
• W2139804581 cites W2168841302 @default.
• W2139804581 cites W2171139285 @default.
• W2139804581 doi "https://doi.org/10.1016/s1470-2045(15)00026-1" @default.
• W2139804581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26051236" @default.
• W2139804581 hasPublicationYear "2015" @default.
• W2139804581 type Work @default.
• W2139804581 sameAs 2139804581 @default.
• W2139804581 citedByCount "696" @default.
• W2139804581 countsByYear W21398045812015 @default.
• W2139804581 countsByYear W21398045812016 @default.
• W2139804581 countsByYear W21398045812017 @default.
• W2139804581 countsByYear W21398045812018 @default.
• W2139804581 countsByYear W21398045812019 @default.
• W2139804581 countsByYear W21398045812020 @default.
• W2139804581 countsByYear W21398045812021 @default.
• W2139804581 countsByYear W21398045812022 @default.
• W2139804581 countsByYear W21398045812023 @default.
• W2139804581 crossrefType "journal-article" @default.
• W2139804581 hasAuthorship W2139804581A5006820907 @default.
• W2139804581 hasAuthorship W2139804581A5032337115 @default.
• W2139804581 hasAuthorship W2139804581A5036507802 @default.
• W2139804581 hasAuthorship W2139804581A5038306289 @default.
• W2139804581 hasAuthorship W2139804581A5041640815 @default.
• W2139804581 hasAuthorship W2139804581A5052670273 @default.
• W2139804581 hasAuthorship W2139804581A5052962058 @default.
• W2139804581 hasAuthorship W2139804581A5053546904 @default.
• W2139804581 hasAuthorship W2139804581A5065884417 @default.
• W2139804581 hasAuthorship W2139804581A5066717752 @default.
• W2139804581 hasAuthorship W2139804581A5072123060 @default.
• W2139804581 hasAuthorship W2139804581A5075333926 @default.
• W2139804581 hasAuthorship W2139804581A5081371583 @default.
• W2139804581 hasConcept C104317684 @default.
• W2139804581 hasConcept C121608353 @default.
• W2139804581 hasConcept C126322002 @default.
• W2139804581 hasConcept C142724271 @default.
• W2139804581 hasConcept C143998085 @default.
• W2139804581 hasConcept C176944494 @default.
• W2139804581 hasConcept C2776256026 @default.
• W2139804581 hasConcept C2777714996 @default.
• W2139804581 hasConcept C2779438470 @default.
• W2139804581 hasConcept C2780580887 @default.
• W2139804581 hasConcept C2780586478 @default.
• W2139804581 hasConcept C2781182431 @default.
• W2139804581 hasConcept C2908647359 @default.
• W2139804581 hasConcept C36823959 @default.
• W2139804581 hasConcept C501734568 @default.
• W2139804581 hasConcept C502942594 @default.
• W2139804581 hasConcept C54355233 @default.
• W2139804581 hasConcept C71924100 @default.
• W2139804581 hasConcept C86803240 @default.
• W2139804581 hasConcept C99454951 @default.
• W2139804581 hasConceptScore W2139804581C104317684 @default.

• next